Call Us 080-41656200 (Mon-Sat: 10AM-8PM)
Free Shipping above Rs. 1499
Cash On Delivery*

Incretins, dipeptidyl peptidase-4 inhibitors and diabetes


Marketed By :  LAP LAMBERT Academic Publishing   Sold By :  Kamal Books International  
Delivery in :  10-12 Business Days


Check Your Delivery Options

Rs. 3,651

Availability: In stock

  • Product Description

Diabetes mellitus is one of the most common problems caused by a combination of insulin resistance and impaired insulin secretion by pancreatic B cells. Nowadays, there are many drugs to treat diabetes. Oral antidiabetic drugs are associated with side effects such as weight gain, hypoglycaemia, lactate acidosis and none of these drugs have been shown to stop the progressive decline of beta-cell function. Insulin treatment is expensive and troublesome for the patients, and also induces weight gain. Given this background, there is a need for new classes of blood-glucose-lowering drugs that minimise the risk of hypoglycaemia. Incretin hormones derivatives and dipeptidyl peptidase-4 inhibitors are the latest marketed development in this field. Incretin hormones (GLP-1 and GIP) amplify insulin secretion and are rapidly degraded by dipeptidyl peptidase-4, therefore two strategies have been pursued to exploit the beneficial actions of the hormone:(I) development of more stable activators of the GLP-1 receptor (so-called incretin) like liraglutide, taspoglutide and so on (II) inhibitors of DPP-4 like alogloptin, dutagliptin and so on. This book surveys new drugs and therapies in diabetes.

Product Specifications
SKU :COC30191
AuthorRobab Sheikhpour
Number of Pages112
Publishing Year8/30/2012
Edition1 st
Book TypeMedicine
Country of ManufactureIndia
Product BrandLAP LAMBERT Academic Publishing
Product Packaging InfoBox
In The Box1 Piece
Product First Available On ClickOnCare.com2015-07-31 00:00:00